Patient Gateway

RSS Feed

Correction: An IHC-derived TLS–CD8–macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC

Co-medications and gut microbiome in NSCLC immunotherapy

Evolving non-invasive biomarkers in NSCLC immunotherapy: integrating liquid biopsy and multi-omics profiling for precision oncology

ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC

YH42946, a novel and selective tyrosine kinase inhibitor, demonstrates potent antitumor activity against EGFR exon 20 insertion mutations and HER2 alterations in NSCLC

Exosomal PD-L1 level in plasma as a predictive marker for prognostic and clinical correlation in NSCLC

Oliver Illini: Trastuzumab Deruxtecan Activity in HER2-Mutant NSCLC

Adjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC

Optimizing Frontline Therapeutic Strategies in EGFR-Mutated Advanced NSCLC